Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback